WAVE Life Sciences (WVE) no longer intends to offers ordinary shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
B.Riley Reiterates Buy Rating on WAVE Life Sciences (WVE)
September 25, 2024 6:24 AM EDTB.Riley analyst Madison El-Saadi reiterated a Buy rating and $11.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "In totality, we believe results exceeded our/investor expectations (9/18 initiation) and replicated the preclinical and early clinical datasets indicative of best-in-class exon skipping profile... More



